Analyst Price Target is $25.67
▲ +316.67% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for MeiraGTx in the last 3 months. The average price target is $25.67, with a high forecast of $41.00 and a low forecast of $11.00. The average price target represents a 316.67% upside from the last price of $6.16.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in MeiraGTx. This Buy consensus rating has held steady for over two years.
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.